To assess the beneficial and harmful effects of drugs improving insulin resistance for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
This is a protocol.
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
You may also be interested in:
- No evidence to support or refute antioxidant supplements for patients with non-alcoholic fatty liver disease and/or steatohepatitis
- No evidence to support or refute probiotics for patients with non-alcoholic fatty liver disease and/or steatohepatitis
- Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with suspected non-alcoholic fatty liver disease
- Bariatric surgery for non-alcoholic steatohepatitis in obese patients
- Weight reduction for non-alcoholic fatty liver disease
Health topics: